Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednis...
Saved in:
| Published in | Journal of clinical oncology Vol. 35; no. 5; pp. 536 - 543 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society of Clinical Oncology
10.02.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20
PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective. |
|---|---|
| AbstractList | Purpose
The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction.
Patients and Methods
In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20
+
PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population.
Results
One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification.
Conclusion
In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective. Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20+ PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20 PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective. Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles of rituximab followed by four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified response to rituximab induction as a prognostic factor for overall survival. We hypothesized that rituximab consolidation might be sufficient treatment for patients with a complete response after rituximab induction. Patients and Methods In this prospective, international, multicenter phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20+ PTLD unresponsive to immunosuppression reduction, were treated with four weekly doses of rituximab induction. After restaging, complete responders continued with four courses of rituximab consolidation every 21 days; all others received four courses of rituximab plus CHOP chemotherapy every 21 days. The primary end point was treatment efficacy measured as the response rate in patients who completed therapy and the response duration in those who completed therapy and responded. Secondary end points were frequency of infections, treatment-related mortality, and overall survival in the intention-to-treat population. Results One hundred eleven of 126 patients had a complete or partial response (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%). Median response duration was not reached. The 3-year estimate was 82% (95% CI, 74% to 90%). Median overall survival was 6.6 years (95% CI, 5.5 to 7.6 years). The frequency of grade 3 or 4 infections and of treatment-related mortality was 34% (95% CI, 27% to 42%) and 8% (95% CI, 5% to 14%), respectively. Response to rituximab induction remained a prognostic factor for overall survival despite treatment stratification. Conclusion In B-cell PTLD, treatment stratification into rituximab or rituximab plus CHOP consolidation on the basis of response to rituximab induction is feasible, safe, and effective. |
| Author | Morschhauser, Franck Dreyling, Martin H Kliem, Volker Zimmermann, Heiner Anagnostopoulos, Ioannis Trappe, Ralf U Tousseyn, Thomas Subklewe, Marion Tarella, Corrado Salles, Gilles Riess, Hanno Choquet, Sylvain Verhoef, Gregor Hauser, Ingeborg A Mollee, Peter Reinke, Petra Dierickx, Daan Zaucha, Jan M Van Den Neste, Eric Gheysens, Olivier Leblond, Veronique Dührsen, Ulrich Hüttmann, Andreas |
| Author_xml | – sequence: 1 givenname: Ralf U surname: Trappe fullname: Trappe, Ralf U organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 2 givenname: Daan surname: Dierickx fullname: Dierickx, Daan organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 3 givenname: Heiner surname: Zimmermann fullname: Zimmermann, Heiner organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 4 givenname: Franck surname: Morschhauser fullname: Morschhauser, Franck organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 5 givenname: Peter surname: Mollee fullname: Mollee, Peter organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 6 givenname: Jan M surname: Zaucha fullname: Zaucha, Jan M organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 7 givenname: Martin H surname: Dreyling fullname: Dreyling, Martin H organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 8 givenname: Ulrich surname: Dührsen fullname: Dührsen, Ulrich organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 9 givenname: Petra surname: Reinke fullname: Reinke, Petra organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 10 givenname: Gregor surname: Verhoef fullname: Verhoef, Gregor organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 11 givenname: Marion surname: Subklewe fullname: Subklewe, Marion organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 12 givenname: Andreas surname: Hüttmann fullname: Hüttmann, Andreas organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 13 givenname: Thomas surname: Tousseyn fullname: Tousseyn, Thomas organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 14 givenname: Gilles surname: Salles fullname: Salles, Gilles organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 15 givenname: Volker surname: Kliem fullname: Kliem, Volker organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 16 givenname: Ingeborg A surname: Hauser fullname: Hauser, Ingeborg A organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 17 givenname: Corrado surname: Tarella fullname: Tarella, Corrado organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 18 givenname: Eric surname: Van Den Neste fullname: Van Den Neste, Eric organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 19 givenname: Olivier surname: Gheysens fullname: Gheysens, Olivier organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 20 givenname: Ioannis surname: Anagnostopoulos fullname: Anagnostopoulos, Ioannis organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 21 givenname: Veronique surname: Leblond fullname: Leblond, Veronique organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 22 givenname: Hanno surname: Riess fullname: Riess, Hanno organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy – sequence: 23 givenname: Sylvain surname: Choquet fullname: Choquet, Sylvain organization: Ralf U. Trappe and Heiner Zimmermann, DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen; University Medical Centre Schleswig-Holstein, Kiel; Ralf U. Trappe, Petra Reinke, Ioannis Anagnostopoulos, and Hanno Riess, Charité-Universitätsmedizin Berlin, Berlin; Martin H. Dreyling and Marion Subklewe, University of Munich, Munich; Ulrich Dührsen and Andreas Hüttmann, University of Duisburg-Essen, Essen; Volker Kliem, Nephrological Centre Lower Saxony, Hann. Münden; Ingeborg A. Hauser, J.W. Goethe University Hospital, Frankfurt, Germany; Daan Dierickx, Gregor Verhoef, Thomas Tousseyn, and Olivier Gheysens, Catholic University Leuven, Leuven; Eric Van Den Neste, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Franck Morschhauser, Hôpital Claude Huriez, Lille; Gilles Salles, Hospices Civils de Lyon and Université de Lyon, Pierre-Bénite; Veronique Leblond and Sylvain Choquet, Université Pierre et Marie Curie, Paris, France; Peter Mollee, University of Queensland, Brisbane, Queensland, Australia; Jan M. Zaucha, Medical University of Gdansk, Gdansk; Polish Lymphoma Research Group, Warsaw, Poland; and Corrado Tarella, European Institute of Oncology, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27992268$$D View this record in MEDLINE/PubMed https://univ-lyon1.hal.science/hal-01796181$$DView record in HAL |
| BookMark | eNpVks2P0zAQxS20iO0u3DkhH0HaFDtu4uTYDR8t6qpVt0jcIscZqwbXDnayH_84Z5x2WYmT7dHvjd-M3gU6s84CQm8pmdKUkI_fqvU0JTSf5uWUZfnsBZrQLOUJ51l2hiaEszShBftxji5C-EkInRUse4XOU16WaZoXE_RnC6FzNgDuHd7qfnjQB9HgpW0H2Wtn8TJggTceWh3fd4BvhP8FHmuLr5MKjMEbF_pk54UNnRG2x6vHQ7d3nXdGK_DiKPqkg_NtlAnb4rkx7j7g20FKCEENBt_2I6e0FKcv7X9enMfbpFqsN7iKRmPb9oRFC-IIg7fHijBX0akLHRytXuGbwfRawkjgzV7EIZdLvPNamNfopRImwJun8xJ9__J5Vy2S1frrspqvEsl41ifQkhJkvEsmZCMgB5IrNaNKFU0sp1nesjJtOW9YShVTrCVNDoxyxXlJCmCX6MOp716YuvNxHv9YO6HrxXxVjzVCeZnTgt7RyL4_sXF3vwcIfX3QQcYVCwtuCDUtMpqWhJUjSk6ojOMGD-q5NyX1mIw6JqMek1HnZT0mI0rePXUfmgO0z4J_UWB_AS-yu3Q |
| CitedBy_id | crossref_primary_10_1097_TP_0000000000002269 crossref_primary_10_3390_jcm11247542 crossref_primary_10_5348_100115Z10VA2022CR crossref_primary_10_1111_bjh_15263 crossref_primary_10_1093_ndt_gfaa219 crossref_primary_10_1111_bjh_18498 crossref_primary_10_1016_j_eimc_2020_01_021 crossref_primary_10_1080_10428194_2017_1413187 crossref_primary_10_3389_frtra_2024_1339898 crossref_primary_10_1053_j_semnuclmed_2020_12_009 crossref_primary_10_5500_wjt_v12_i8_268 crossref_primary_10_1007_s00277_018_03591_w crossref_primary_10_1016_j_semnephrol_2024_151503 crossref_primary_10_1007_s00277_018_3473_8 crossref_primary_10_1080_0284186X_2021_1904520 crossref_primary_10_1016_j_blre_2021_100807 crossref_primary_10_3324_haematol_2022_282297 crossref_primary_10_1016_j_semnephrol_2024_151501 crossref_primary_10_1155_2021_6587323 crossref_primary_10_1097_TP_0000000000004577 crossref_primary_10_1016_j_jaccao_2022_09_002 crossref_primary_10_3324_haematol_2023_282831 crossref_primary_10_1080_10428194_2021_1964023 crossref_primary_10_1111_bjh_18763 crossref_primary_10_1007_s11899_021_00606_8 crossref_primary_10_1182_bloodadvances_2023011626 crossref_primary_10_1186_s13550_021_00769_8 crossref_primary_10_1136_bcr_2022_253105 crossref_primary_10_13105_wjma_v11_i7_317 crossref_primary_10_1111_petr_14781 crossref_primary_10_1097_TXD_0000000000001129 crossref_primary_10_1111_tri_13952 crossref_primary_10_1016_j_clml_2020_11_006 crossref_primary_10_1111_ajt_16385 crossref_primary_10_3389_fonc_2019_00109 crossref_primary_10_1038_s41375_022_01667_1 crossref_primary_10_1038_s41409_019_0548_7 crossref_primary_10_1111_bjh_17421 crossref_primary_10_1002_cnr2_1375 crossref_primary_10_1186_s13550_024_01111_8 crossref_primary_10_1136_jitc_2020_000736 crossref_primary_10_1016_j_transproceed_2020_08_004 crossref_primary_10_1111_tri_13624 crossref_primary_10_1182_blood_2022016975 crossref_primary_10_3390_cancers13236021 crossref_primary_10_1080_21556660_2020_1854561 crossref_primary_10_1097_HS9_0000000000000226 crossref_primary_10_12998_wjcc_v9_i3_748 crossref_primary_10_1111_ajt_16367 crossref_primary_10_1097_MPH_0000000000002804 crossref_primary_10_1053_j_ackd_2021_09_002 crossref_primary_10_1097_TXD_0000000000001584 crossref_primary_10_1097_HS9_0000000000000640 crossref_primary_10_1182_blood_2020005466 crossref_primary_10_1007_s00467_020_04790_2 crossref_primary_10_1111_bjh_18065 crossref_primary_10_1080_17474086_2021_1935851 crossref_primary_10_1016_S1470_2045_23_00649_6 crossref_primary_10_1016_j_transproceed_2018_02_168 crossref_primary_10_3389_fcvm_2022_787975 crossref_primary_10_1016_j_eimce_2020_01_019 crossref_primary_10_1080_10428194_2019_1636981 crossref_primary_10_1097_MNH_0000000000000457 crossref_primary_10_3390_cancers10040112 crossref_primary_10_1002_ccr3_4111 crossref_primary_10_3390_cancers14235949 crossref_primary_10_1080_21556660_2022_2073101 crossref_primary_10_1007_s00277_021_04433_y crossref_primary_10_1016_j_beha_2023_101446 crossref_primary_10_1016_j_semnephrol_2022_01_003 crossref_primary_10_4239_wjd_v15_i6_1111 crossref_primary_10_1097_CCO_0000000000000885 crossref_primary_10_1097_HS9_0000000000000648 crossref_primary_10_1038_s41409_021_01270_5 crossref_primary_10_1111_ctr_14910 crossref_primary_10_12998_wjcc_v7_i24_4299 crossref_primary_10_3389_ti_2022_10707 crossref_primary_10_1182_blood_2023020075 crossref_primary_10_1016_j_trre_2021_100636 crossref_primary_10_1007_s11864_018_0549_6 crossref_primary_10_3390_cancers15113046 crossref_primary_10_1007_s00277_020_04198_w crossref_primary_10_1111_bjh_16304 crossref_primary_10_1007_s12325_022_02383_z crossref_primary_10_1111_ajt_14603 crossref_primary_10_52604_alt_21_0014 crossref_primary_10_1111_bjh_19255 crossref_primary_10_1016_S1245_1789_23_47715_3 crossref_primary_10_1007_s00467_021_05205_6 crossref_primary_10_1056_NEJMra1702693 crossref_primary_10_1016_j_healun_2022_09_023 crossref_primary_10_1111_ctr_13652 crossref_primary_10_1182_bloodadvances_2021006156 crossref_primary_10_3389_fonc_2021_726134 crossref_primary_10_1055_a_1374_4192 crossref_primary_10_1016_j_cpet_2020_03_006 crossref_primary_10_1016_j_suc_2018_09_004 crossref_primary_10_1080_10428194_2021_1957867 crossref_primary_10_3390_cancers13040899 crossref_primary_10_1007_s12308_019_00364_w crossref_primary_10_3389_ti_2023_11856 crossref_primary_10_3390_cancers14081953 crossref_primary_10_1016_j_blre_2023_101167 crossref_primary_10_1097_TP_0000000000002006 crossref_primary_10_1172_JCI121127 crossref_primary_10_3390_vaccines9060555 crossref_primary_10_1080_08880018_2019_1637982 crossref_primary_10_1002_jha2_247 crossref_primary_10_1111_petr_13861 crossref_primary_10_1016_j_healun_2022_10_015 crossref_primary_10_1111_bjh_16371 crossref_primary_10_14309_crj_2018_10 crossref_primary_10_1007_s11894_021_00811_8 crossref_primary_10_1111_petr_13747 crossref_primary_10_1007_s00277_021_04548_2 crossref_primary_10_3389_fped_2022_1087864 crossref_primary_10_2215_CJN_00180119 crossref_primary_10_1080_0284186X_2019_1598622 crossref_primary_10_1016_j_bbmt_2018_02_026 crossref_primary_10_1111_ajt_14303 crossref_primary_10_1007_s11912_023_01418_0 crossref_primary_10_1080_10428194_2020_1821006 crossref_primary_10_2147_IDR_S301153 crossref_primary_10_1080_10428194_2018_1474462 crossref_primary_10_1016_j_clml_2021_05_009 crossref_primary_10_1097_TP_0000000000003183 crossref_primary_10_1111_bjh_19355 crossref_primary_10_1111_ejh_12988 crossref_primary_10_1016_j_trre_2024_100837 crossref_primary_10_1097_HS9_0000000000000833 crossref_primary_10_1007_s12325_017_0612_x crossref_primary_10_1177_09636897241259722 crossref_primary_10_1007_s00277_020_04056_9 crossref_primary_10_1053_j_ajkd_2021_01_015 crossref_primary_10_1155_2017_6401086 crossref_primary_10_1111_bjh_18828 crossref_primary_10_1111_tri_13652 crossref_primary_10_5500_wjt_v10_i2_29 |
| Cites_doi | 10.1056/NEJM199309303291402 10.1111/j.1600-6143.2012.04206.x 10.1182/asheducation-2013.1.95 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H 10.1016/S1470-2045(06)70664-7 10.1007/s00277-007-0298-2 10.1097/TP.0b013e31829b0868 10.1111/ajt.13086 10.1111/ajt.12119 10.1182/blood-2015-05-615872 10.3324/haematol.11360 10.1385/MO:21:3:273 10.1086/651262 10.1182/blood-2005-04-1437 10.1200/JCO.2000.18.21.3622 10.1016/S0140-6736(84)90994-2 10.1097/01.tp.0000228906.31675.fb 10.1111/j.1600-6143.2005.01098.x 10.1111/j.1365-2141.2006.06228.x 10.1016/S1470-2045(08)70002-0 10.1182/blood-2005-01-0377 10.1056/NEJMoa011795 10.1016/S1470-2045(11)70300-X 10.1002/cncr.21391 10.3324/haematol.10595 10.1111/j.1600-6143.2005.01211.x 10.1002/pds.3320 |
| ContentType | Journal Article |
| Copyright | Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | NPM AAYXX CITATION 7X8 1XC |
| DOI | 10.1200/JCO.2016.69.3564 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| EndPage | 543 |
| ExternalDocumentID | oai_HAL_hal_01796181v1 10_1200_JCO_2016_69_3564 27992268 |
| Genre | Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQOH AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY AAYXX CITATION 7X8 .GJ 08G 08P 1XC 29K 3O- 5VS 8WZ A6W AAKAS AAQQT ADZCM AFFNX AI. ASPBG AVWKF AZFZN D-I EX3 FEDTE HVGLF IPNFZ J5H N4W NTWIH RIG UHU VH1 WOQ WOW ZGI |
| ID | FETCH-LOGICAL-c375t-ed09ecc37c3acbae6e06ff41ff8bcc3256d392d77b321f3f3d0b6e317f77908e3 |
| ISSN | 0732-183X |
| IngestDate | Fri Sep 06 12:42:12 EDT 2024 Wed Jul 24 19:35:40 EDT 2024 Fri Aug 23 03:16:50 EDT 2024 Sat Sep 28 08:49:25 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | methods Berlin therapy Rituximab Prednisone Lymphoma Patients Doxorubicin Survival Transplant Recipients Vincristine secondary Infection Cyclophosphamide Immunosuppression Belgium mortality Adult Italy Population France Germany |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c375t-ed09ecc37c3acbae6e06ff41ff8bcc3256d392d77b321f3f3d0b6e317f77908e3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-9541-8666 0000-0002-3714-9824 |
| OpenAccessLink | https://lirias.kuleuven.be/bitstream/123456789/574432/1/Jclin%20onc.pdf |
| PMID | 27992268 |
| PQID | 1851290391 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | hal_primary_oai_HAL_hal_01796181v1 proquest_miscellaneous_1851290391 crossref_primary_10_1200_JCO_2016_69_3564 pubmed_primary_27992268 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-10 |
| PublicationDateYYYYMMDD | 2017-02-10 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2017 |
| Publisher | American Society of Clinical Oncology |
| Publisher_xml | – name: American Society of Clinical Oncology |
| References | B20 B21 B22 B23 B24 B25 B26 B27 B28 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B1 B2 B3 B4 B5 B6 B7 B8 B9 |
| References_xml | – ident: B19 doi: 10.1056/NEJM199309303291402 – ident: B4 doi: 10.1111/j.1600-6143.2012.04206.x – ident: B1 doi: 10.1182/asheducation-2013.1.95 – ident: B3 – ident: B9 doi: 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H – ident: B17 doi: 10.1016/S1470-2045(06)70664-7 – ident: B27 doi: 10.1007/s00277-007-0298-2 – ident: B20 doi: 10.1097/TP.0b013e31829b0868 – ident: B21 doi: 10.1111/ajt.13086 – ident: B23 doi: 10.1111/ajt.12119 – ident: B2 doi: 10.1182/blood-2015-05-615872 – ident: B8 doi: 10.3324/haematol.11360 – ident: B11 doi: 10.1385/MO:21:3:273 – ident: B24 doi: 10.1086/651262 – ident: B18 doi: 10.1182/blood-2005-04-1437 – ident: B10 doi: 10.1200/JCO.2000.18.21.3622 – ident: B26 doi: 10.1016/S0140-6736(84)90994-2 – ident: B14 doi: 10.1097/01.tp.0000228906.31675.fb – ident: B6 doi: 10.1111/j.1600-6143.2005.01098.x – ident: B13 doi: 10.1111/j.1365-2141.2006.06228.x – ident: B22 doi: 10.1016/S1470-2045(08)70002-0 – ident: B7 doi: 10.1182/blood-2005-01-0377 – ident: B16 doi: 10.1056/NEJMoa011795 – ident: B5 doi: 10.1016/S1470-2045(11)70300-X – ident: B28 doi: 10.1002/cncr.21391 – ident: B15 doi: 10.3324/haematol.10595 – ident: B12 doi: 10.1111/j.1600-6143.2005.01211.x – ident: B25 doi: 10.1002/pds.3320 |
| SSID | ssj0014835 |
| Score | 2.6126695 |
| Snippet | Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548)... Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548)... |
| SourceID | hal proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 536 |
| SubjectTerms | Cancer Life Sciences |
| Title | Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27992268 https://search.proquest.com/docview/1851290391 https://univ-lyon1.hal.science/hal-01796181 |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3fb9MwEMetbUiIlwnGr_FLB0KTUJqtaZqkeRwV0KCNVVUnTbxETmKrFV1SNSls_OE8c2fnR1s2CXiJosRy0tyn9tk-f4-xt5HjJz23Z5ku4mJ27USavowtU2J_EMkYOzSlwHf6xR2cdz9fOBdb27srUUvLIjqMf964r-R_rIrX0K60S_YfLFtXihfwHO2LR7QwHv_KxiMd4KqyX4ymxfJqeskjg7Jx6ATgQW5wCrJIpqpVUxtzBMWfG-_Nvpq0y_LC1PrmM_zExsk1GjebUyYfKUpN8EqfUy0zHM9m2Y8cmxuVZ5Him5W8LcUbaZKCdO1dsoUxMvuDs6HKDIrV6hRO9Ap8YzpS-bOLrNr6qWZqlTYIqYYujOEE-1sjCIwxfdhbfOp6n2eWxmvrBfgb53NV54jPpHFe--9TWrD6dqXD-5t_ytcpTehflhmkB4K2SNZsZos8nkw4ze9Uvn-ZWqCcPsEumZK56JUgUTb5HQ_HGFosuOoTtIRKyb6z0sA7Wq7lj46no3Nq988oWtA9dP1D29Hy7Csczi8ViB2PxIB1NqENse_q1ja7g6cOzSZ8uqhjlnDoajvlWjs-8GjzcaRsXVaw5mZtTyjI97YRlPKkxvfZbmkuONY8P2BbIt1jd0_LII89djDUcurXLRg3uwPzFhzAsBFav37IflX8Q5FBzRzU_EOQA4eGf9D8wzQFzT9s8A838A8V_4D8g-YfGv5hnX8g_lfeJVuA5h_W-KdX4Kpww38LVuhvwQr7oNiHIADF_iN2_vHDuD8wyzwmZmx7TmGKpO1jS2l7sc3jiAtXtF0pu5aUvQgv46AjwVFK4nmR3bGkLe2kHbkCHXtJYqA9YT9mO2mWiqcMeq5D5dAtx6GWFILzLhYTsdXueRYX_j57V5k9nGu5mpCG-R1as-6fhURL6Poh0bLP3iAXdTHSmR8cn4R0jbppFx_y3dpnrytsQux4aDWRpyJb5iE6-jSHbftY5onmqa6rovDZrXees3vNv_EF2ykWS_ES3fsieqWQ_w1WPQUH |
| link.rule.ids | 230,315,786,790,891,27957,27958 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Response+to+Rituximab+Induction+Is+a+Predictive+Marker+in+B-Cell+Post-Transplant+Lymphoproliferative+Disorder+and+Allows+Successful+Stratification+Into+Rituximab+or+R-CHOP+Consolidation+in+an+International%2C+Prospective%2C+Multicenter+Phase+II+Trial&rft.jtitle=Journal+of+clinical+oncology&rft.au=Trappe%2C+Ralf+U&rft.au=Dierickx%2C+Daan&rft.au=Zimmermann%2C+Heiner&rft.au=Morschhauser%2C+Franck&rft.date=2017-02-10&rft.eissn=1527-7755&rft.volume=35&rft.issue=5&rft.spage=536&rft_id=info:doi/10.1200%2FJCO.2016.69.3564&rft_id=info%3Apmid%2F27992268&rft.externalDocID=27992268 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |